AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03499223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham injection
Description: 3 sham injections, approximately 1 month apart. No actual injections. No medication is used.
Study NCT02697786 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial doppler
Description: Prolonged de airing to decrease the number of MES
Study NCT02697786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial doppler
Description: Prolonged de airing to decrease the number of MES
Study NCT01120223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)
Description: Once daily application
Study NCT00533845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: On-Q Pain Pump
Description: Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally
Study NCT00533845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: On-Q Pain Pump
Description: Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally
Study NCT00728780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-143
Description: once
Study NCT00728780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335 and rosuvastatin
Description: once
Study NCT03692364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceramic-on-ceramic uncemented hip arthroplasty
Study NCT03692364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metal-on-polyethylene uncemented total hip arthroplasty
Study NCT02769325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: IV atropine 0.1%, 10 ml
Study NCT02769325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV saline, 10 ml
Study NCT02769325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: All patients will receive anaesthesia based on sevoflurane, titrated to a bis of 45-60
Study NCT02769325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: All patients will receive anaesthesia based on sevoflurane, titrated to a bis of 45-60
Study NCT02769325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: Patients will receive sugamadex for neuromuscular reversion, if necessary
Study NCT02769325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugammadex
Description: Patients will receive sugamadex for neuromuscular reversion, if necessary
Study NCT02769325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period
Study NCT02769325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac
Description: 60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period
Study NCT02769325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine PCA
Description: Patients will receive a PCA of morphine with a program of 0 (continuous infusion), 1 mg bolus and 8 minutes lockout
Study NCT02769325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine PCA
Description: Patients will receive a PCA of morphine with a program of 0 (continuous infusion), 1 mg bolus and 8 minutes lockout
Study NCT04196309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecular weight heparin
Description: LMWH (tinzaparin) at body-weight-adjusted therapeutic dose (175 anti-Xa IU/kg subcutaneously once daily)
Study NCT03270709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 450,000 IU orally
Description: Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.
Study NCT03270709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 450,000 IU orally
Description: Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.
Study NCT02769325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium
Description: general anaesthesia will use rocuronium 0.6 mg/kg to facilitate intubation
Study NCT02769325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rocuronium
Description: general anaesthesia will use rocuronium 0.6 mg/kg to facilitate intubation
Study NCT02769325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: for anaesthesia induction, patients will receive 2-3 mg/kg iv propofol
Study NCT02769325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol
Description: for anaesthesia induction, patients will receive 2-3 mg/kg iv propofol
Study NCT01986660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Cream (SST-0225)
Study NCT02140229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: US power doppler
Description: Clinical evaluation according to DAS28 and US every 3 months. US examination is realized in B and Doppler power mode for each studied joint: Ankles, shoulders, elbows, wrists, MCP 1 to 5, PIP 1 to 5, knees and MTP 1 to 5.
Study NCT02140229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Clinical evaluation and follow-up according to the practice of the referring rheumatologist every 3 months
Study NCT02140229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACR/EULAR criteria
Description: Evaluation based on clinical evaluation according to DAS28 and ACR/EULAR remission criteria every 3 months.
Study NCT03985774 — intervention group
Intervention type: PROCEDURE
Intervention: Transcarotid revascularization
Description: The ENROUTE Transcarotid Neuroprotection System (NPS) has received CE Mark and is commercially available in the European Union. The ENROUTE Transcarotid NPS may be used in conjunction with carotid artery stent approved for revascularization in patients with carotid disease The ENROUTE Transcarotid Neuroprotection System is intended to provide transcarotid vascular access, introduction of diagnostic agents and therapeutic devices, and embolic protection during carotid artery angioplasty and stenting procedures for patients diagnosed with carotid artery stenosis
Study NCT03272828 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nobel Biocare titanium dental implants
Study NCT04465539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl Starch 130-0.4 60 MG/ML [Voluven]
Description: Hydroxyethyl starch dose is 500 cc in 6 hours
Study NCT00895609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex, Neostigmine, Saline
Description: Single intravenous injection of either:~Sugammadex 0.0625 mg/kg (Sgx 0.0625) Sugammadex 0.125 mg/kg (Sgx 0.125) Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 1.0 mg/kg (Sgx 1.0) Neostigmine 5 mg/kg (Neo 5) Neostigmine 8 mg/kg (Neo 8) Neostigmine 15 mg/kg (Neo 15) Neostigmine 25 mg/kg (Neo 25) Neostigmine 40 mg/kg (Neo 40) Saline 0.9% (Saline)
Study NCT00895609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex, Neostigmine, Saline
Description: Single intravenous injection of either:~Sugammadex 0.0625 mg/kg (Sgx 0.0625) Sugammadex 0.125 mg/kg (Sgx 0.125) Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 1.0 mg/kg (Sgx 1.0) Neostigmine 5 mg/kg (Neo 5) Neostigmine 8 mg/kg (Neo 8) Neostigmine 15 mg/kg (Neo 15) Neostigmine 25 mg/kg (Neo 25) Neostigmine 40 mg/kg (Neo 40) Saline 0.9% (Saline)
Study NCT03594305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational seminar
Description: Religious leaders will be invited to participate in a one-day seminar led by Tanzanian religious leaders and physicians. The religious, cultural, and medical aspects of family planning will be discussed and seminar attendees will be given ample time for group discussions.
Study NCT04465539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone dose is 200-300 mg /day intravenously
Study NCT04465539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.
Study NCT04465539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.
Study NCT02528656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Bell
Description: Patients will be submitted to a negative pressure treatment with the Vacuum Bell device.
Study NCT02528656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Compression System
Description: Patients will be submitted to a dynamic compression system.
Study NCT01950845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed loop automated System (LIR®: learning intravenous resuscitator)
Description: Connection of the system to the patient under supervision of the anesthesiologist team during all the anesthesia procedure, respective of the applicability criteria for the fluid responsiveness detection.
Study NCT01950845 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: manual current practice by anesthesiologist team
Description: The anesthesiologist team will manage the fluid administration during all the anesthesia procedure.
Study NCT03219489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic medical record alert
Description: An electronic medical record alert will be inserted into the clinic's electronic medical records. The alert reads: Consider Progesterone 100-200 mg pv qhs > or =16 weeks, if previous spontaneous PTB or current short cervix, and no allergies to peanuts or progesterone.~This alert will appear on the Ministry of Health-mandated Perinatal Records.
Study NCT04060550 — intervention group
Intervention type: BIOLOGICAL
Intervention: Xolair
Description: This is in vitro mechanistic study. No drug will be given in vivo to patients.
Study NCT04537507 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary angiography
Study NCT03447132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant 500mg
Description: All patients in all arms will receive Fulvestrant 500mg
Study NCT03447132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant 500mg
Description: All patients in all arms will receive Fulvestrant 500mg
Study NCT03447132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib 125mg
Description: Dose reduction to 100 mg and 75 mg
Study NCT03447132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin 3.6 MG
Description: Only for pre or peri menopausal patient
Study NCT03447132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Goserelin 3.6 MG
Description: Only for pre or peri menopausal patient
Study NCT03447132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study NCT00612924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anaconda Stent Graft System
Description: Endovascular device
Study NCT00612924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anaconda ONE-LOK Stent Graft System
Description: Endovascular device
Study NCT03362398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omarigliptin 25 mg
Description: Once weekly new anti-diabetic drug approved only in Japan
Study NCT03362398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trelagliptin 100 mg
Description: Once weekly new anti-diabetic drug approved only in Japan
Study NCT03970161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: routine ophthalmic examination
Description: Routine ophthalmic examination, including slit lamp, intraocular pressure, and fundus examinations using direct or indirect ophthalmoscopy after pupil dilation and optical coherence tomography (OCT) examination. Patients with DM also underwent fundus fluorescein angiography (FFA) examination.
Study NCT04185649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAT8001 for injection
Description: 3.6 mg/kg, q3w, administered intravenously on day 1 of each treatment cycle, 21 days/treatment cycle.
Study NCT04185649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
Study NCT04185649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
Study NCT05504304 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open reduction and internal fixation plus primary subtalar arthrodesis
Description: they will be scheduled to surgery after resolution of the edema and appearance of wrinkle sign. Lateral position and lateral extensile approach will be used. A 4 mm schanz will be inserted in the calcaneal tuberosity from lateral side to control varus and to restore calcaneal height. Lateral wall of the calcaneus will be lifted keeping it attached inferiorly. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. tricortical iliac bone autograft will be inserted the subtalar joint. A lateral nonlocked plate will be applied to reduce the lateral wall blow out and broadening then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
Study NCT05504304 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conservative management then calcaneoplasty and subtalar arthrodesis.
Description: they will be assessed upon 1st clinic visit. After at least three months patients will be scheduled for subtalar arthrodesis. A new preoperative ankle CT scan will be done. Lateral position and lateral extensile approach will be used. Lateral wall and plantar exostosis will be resected. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. Hind foot deformity (mostly varus) will be corrected through the subtalar joint manually and checked clinically. Loss of calcaneal height will be corrected by tricortical iliac bone autograft to distract the subtalar joint then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
Study NCT03926000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin (PG)
Description: Pregabalin 150 mg one hour before the procedure as premedication.
Study NCT03926000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control placebo (C)
Description: Placebo tablets one hour before the procedure as premedication.
Study NCT05596617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral bedtime melatonin
Description: Different doses of oral bedtime melatonin
Study NCT02398851 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TacTic care model
Description: Patients receive care in a trans-disciplinary chronic disease continuity of care model integrated with technology (mobile devices such as tablets, iPads and smartphones
Study NCT02398851 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of care
Description: Patients receive care in a patient-centered, coordinated care model without the integration of technology
Study NCT03999450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief motivational intervention (BMI)
Description: The intervention typically takes 45 minutes to administer and is designed to enhance motivation to change and includes the following components: establishing rapport, asking permission to discuss substance use and providing feedback regarding the substance use assessment, exploring personal consequences of drug use, eliciting the gap between real and desired quality of life, and discussing readiness to change. The therapist then negotiates a written action plan, during which the subject is supported with empathy and verbal reinforcement.
Study NCT03999450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: This evidence-based, online, Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT) program covers six lessons: 1) changing patterns of use, 2) coping with craving, 3) refusing drugs, 4) problem-solving skills, 5) changing drug-related thoughts, and 6) improving decision-making. The program is designed to be user-friendly and includes videotaped instructions and examples, interactive assessments, and practice exercises.
Study NCT02703389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Animated video explaining acute otitis media and antimicrobial stewardship.
Study NCT02703389 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlet
Description: Contains same information as video.
Study NCT04378205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.014-inch NiTi on one side /0.018-inch NiTi on the other side
Description: Where each patient received 2 archwire sizes (0.014-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.
Study NCT04378205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.016-inch NiTi on one side /0.018-inch NiTi on the other side
Description: Where each patient received 2 archwire sizes (0.016-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.
Study NCT03740958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rt-PA
Description: Intravenous throbolysis with 0.9mg/kg rtPA
Study NCT03740958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rt-PA
Description: Intravenous throbolysis with 0.9mg/kg rtPA
Study NCT03740958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: 100 ug/kg bolus over 3 to 5 minutes was administered intravenously, followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
Study NCT02829281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Joint injection of Botulinum Toxin Type A
Study NCT02829281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone hexacetonide
Description: Joint injection of triamcinolone hexacetonide
Study NCT01820403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: portion size kcal of box lunch
Study NCT02059889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Undergo diffusion-weighted MRI
Study NCT02059889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4-dimensional computed tomography
Description: Undergo 4D CT
Study NCT02059889 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG-PET
Study NCT02059889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: Undergo FDG-PET
Study NCT00943475 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: circumcision
Description: circumcision by plastbell
Study NCT02598219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-operative SN mapping with radionucleide
Description: 1. Preparation : four 1ml syringe (Nanocis, or Nanocoll, or Rotop-nanoHSA) are prepared per patient, each containing a total activity 10 MBq if the injection is planned the same day of surgery and in the operative theater OR each containing a total activity 30MBq if the injection is performed the day before the surgery.~2. Intracervical injection is performed by the surgeon, no more than 3-24 hours before surgery : 4 submucous injections with the filtered radiocolloid at 3, 6, 9 and 12 o'clock positions. Each injection if performed at 2 mm of depth for a total activity of 40 MBq or a total activity of 120 MBq is the surgery is planned the day after the injection.~3. Sentinel Node detection by planar scintigraphy at 1 and 3h (if no detection at 1 hour), or by SPECT-CT imaging if available.